Document Detail

Differential effects of continuous versus intermittent administration of growth hormone to hypophysectomized female rats on serum lipoproteins and their apoproteins.
MedLine Citation:
PMID:  2759036     Owner:  NLM     Status:  MEDLINE    
The effects of the plasma pattern of GH on serum and lipoprotein levels of total cholesterol, triglycerides, apolipoprotein A-I (apo A-I), apolipoprotein B 48/100 (apo B), and apolipoprotein E (apo E) were studied in hypophysectomized female Sprague-Dawley rats, which had been given replacement therapy with L-T4 and hydrocortisone. Bovine GH (1 mg/ was administered sc either continuously by means of osmotic minipumps or by two daily injections. Serum lipoproteins were separated by sequential ultracentrifugation into very low density lipoproteins [density (d) less than 1.006 g/ml], low density lipoproteins (LDL; d 1.006-1.063 g/ml) and high density lipoproteins (HDL; d 1.063-1.21 g/ml). The content of total cholesterol and triglycerides were then determined. Apo A-I, apo B, and apo E were isolated from rat serum and antibodies raised in rabbits. In serum and in lipoprotein fractions, the content of apo A-I, apo-B, and apo E were determined by electroimmunoassay. After hypophysectomy, there occurred a decrease in serum cholesterol and serum levels of apo A-I and apo E, in spite of replacement therapy with T4 and cortisone. Similar changes were also observed in HDL. In contrast, apo B, cholesterol, and triglycerides were increased in LDL. Estradiol treatment had no effect on these changes. Continuous infusion of GH resulted in an increase in cholesterol and apo E in serum and HDL to the levels of intact females. In contrast, GH given twice daily had no effect. Therefore, the sexually dimorphic secretion of GH may be important for the regulation of sex differences in apo E and HDL cholesterol levels. There were no consistent effects of GH treatment on the levels of apo A-I in serum or HDL, but GH treatment resulted in a decrease in apo B and triglycerides in both serum and LDL, regardless of the mode of administration. This suggests that GH regulates the serum and LDL levels of apo B and triglycerides independently of the secretory pattern.
J Oscarsson; S O Olofsson; G Bondjers; S Edén
Related Documents :
1731856 - Role of apolipoprotein e on cholesteryl ester-enriched low density lipoprotein particle...
7679376 - Estimation of protective levels of anti-o-specific lipopolysaccharide immunoglobulin g ...
9434096 - Lipopolysaccharide-induced increase in plasma nitrotyrosine concentrations in rats.
2506056 - Polymorphism of apolipoprotein e influences levels of serum apolipoproteins e and b in ...
3757916 - Hypercalcemia in glucocorticoid withdrawal.
940296 - Control of mineralocorticoid substitution in addison's disease by plasma renin measurem...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Endocrinology     Volume:  125     ISSN:  0013-7227     ISO Abbreviation:  Endocrinology     Publication Date:  1989 Sep 
Date Detail:
Created Date:  1989-09-20     Completed Date:  1989-09-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375040     Medline TA:  Endocrinology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1638-49     Citation Subset:  AIM; IM    
Department of Physiology, University of Göteborg, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apolipoproteins / blood*
Body Weight / drug effects
Cholesterol / blood
Drug Administration Schedule
Drug Implants
Growth Hormone / administration & dosage,  pharmacology*
Infusions, Intravenous
Injections, Subcutaneous
Lipoproteins / blood*,  isolation & purification
Molecular Weight
Rats, Inbred Strains
Reference Values
Triglycerides / blood
Reg. No./Substance:
0/Apolipoproteins; 0/Drug Implants; 0/Lipoproteins; 0/Triglycerides; 57-88-5/Cholesterol; 9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pancreastatin, a presumed product of chromogranin-A (secretory protein-I) processing, inhibits secre...
Next Document:  Essential fatty acid deficiency delays the onset of puberty in the female rat.